Do analysts rate KRRO or BCTX?

Korro Bio currently has a consensus price target of $16.71, indicating a potential upside of 73.38%. Given Korro Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Korro Bio is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KRRO or BCTX more profitable?

Korro Bio's return on equity of -114.26% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio N/A -114.26% -68.57% Briacell Therap N/A -153.53% -129.26%

Do analysts recommend BCTX or HUMA?

Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,154.39%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Humacyte 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Is BCTX or HUMA more profitable?

Briacell Therap has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Briacell Therap's return on equity of -153.53% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Humacyte -4,556.29% -983.32% -88.84%

Is RNA or BCTX more profitable?

Avidity Biosciences' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Briacell Therap N/A -153.53% -129.26%

Do analysts rate OTLK or BCTX?

Oncobiologics currently has a consensus price target of $5.20, indicating a potential upside of 776.90%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts clearly believe Oncobiologics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OTLK or BCTX more profitable?

Oncobiologics' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Briacell Therap N/A -153.53% -129.26%

Do analysts rate BCTX or TLSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BCTX or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is BCTX or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Tiziana Life Sciences N/A N/A N/A

Briacell Therap (BCTX) Competitors

$4.04 -0.07 (-1.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.18 +0.15 (+3.59%)

As of 10/2/2026 07:30 PM Eastern

Compare

BCTX vs. KRRO, HUMA, RNA, OTLK, and TLSA

Should you buy Briacell Therap stock or one of its competitors? Briacell Therap's main competitors and comparable companies include Korro Bio (KRRO), Humacyte (HUMA), Avidity Biosciences (RNA), Oncobiologics (OTLK), and Tiziana Life Sciences (TLSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Briacell Therap compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Korro Bio currently has a consensus price target of $16.71, indicating a potential upside of 73.38%. Given Korro Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Korro Bio is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Korro Bio's average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
Korro Bio	Neutral
Briacell Therap	Neutral

Briacell Therap has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	22.22	-$117.26M	-$10.00	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Korro Bio's return on equity of -114.26% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
Briacell Therap	N/A	-153.53%	-129.26%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Korro Bio has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Korro Bio beats Briacell Therap on 9 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to Humacyte?

Briacell Therap (NASDAQ:BCTX) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Humacyte had 5 more articles in the media than Briacell Therap. MarketBeat recorded 5 mentions for Humacyte and 0 mentions for Briacell Therap. Humacyte's average media sentiment score of 0.44 beat Briacell Therap's score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Briacell Therap	Neutral
Humacyte	Neutral

Briacell Therap has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Briacell Therap's return on equity of -153.53% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Humacyte	-4,556.29%	-983.32%	-88.84%

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Briacell Therap has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Humacyte	$2.04M	71.02	-$40.83M	-$0.49	N/A

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,154.39%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Humacyte beats Briacell Therap on 11 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Avidity Biosciences' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Briacell Therap	N/A	-153.53%	-129.26%

15.4% of Briacell Therap shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avidity Biosciences had 1 more articles in the media than Briacell Therap. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Briacell Therap. Avidity Biosciences' average media sentiment score of 1.11 beat Briacell Therap's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Avidity Biosciences	Positive
Briacell Therap	Neutral

Avidity Biosciences currently has a consensus target price of $63.75, suggesting a potential upside of 713.14%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$35.84M	3.74	-$36.78M	-$2.15	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Summary

Avidity Biosciences beats Briacell Therap on 11 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Oncobiologics currently has a consensus price target of $5.20, indicating a potential upside of 776.90%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts clearly believe Oncobiologics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Oncobiologics had 1 more articles in the media than Briacell Therap. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Briacell Therap. Oncobiologics' average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
Oncobiologics	Neutral
Briacell Therap	Neutral

Oncobiologics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Briacell Therap	N/A	-153.53%	-129.26%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Briacell Therap has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Summary

Oncobiologics beats Briacell Therap on 8 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to Tiziana Life Sciences?

Briacell Therap (NASDAQ:BCTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Tiziana Life Sciences had 10 more articles in the media than Briacell Therap. MarketBeat recorded 10 mentions for Tiziana Life Sciences and 0 mentions for Briacell Therap. Tiziana Life Sciences' average media sentiment score of 0.14 beat Briacell Therap's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Briacell Therap	Neutral
Tiziana Life Sciences	Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Tiziana Life Sciences	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

15.4% of Briacell Therap shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Summary

Tiziana Life Sciences beats Briacell Therap on 8 of the 10 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.15M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-0.51	13.06	275.66	26.04
Price / Sales	N/A	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.44	16.63	10.93	6.31
Net Income	-$26.31M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-6.48%	-2.99%	-2.00%	-1.66%
1 Month Performance	14.45%	-10.60%	-6.15%	-4.50%
1 Year Performance	-69.11%	19.44%	7.44%	2.06%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.0918 of 5 stars	$4.04 -1.7%	N/A	-69.1%	$35.15M	N/A	N/A	4
KRRO Korro Bio	2.0532 of 5 stars	$9.88 +3.3%	$16.71 +69.3%	-79.1%	$145.42M	$2.38M	N/A	57	Positive News
HUMA Humacyte	2.2361 of 5 stars	$0.52 -3.1%	$6.54 +1,167.8%	-75.2%	$143.34M	$2.12M	N/A	184
RNA Avidity Biosciences	1.729 of 5 stars	$8.32 -1.2%	$63.75 +666.2%	-83.3%	$142.36M	N/A	N/A	190	Positive News
OTLK Oncobiologics	2.8078 of 5 stars	$0.58 -7.6%	$5.20 +799.7%	-44.1%	$140.71M	-$1.16M	N/A	17	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. KRRO, HUMA, RNA, OTLK, and TLSA

How does Briacell Therap compare to Korro Bio?

Summary

How does Briacell Therap compare to Humacyte?

Summary

How does Briacell Therap compare to Avidity Biosciences?

Summary

How does Briacell Therap compare to Oncobiologics?

Summary

How does Briacell Therap compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. KRRO, HUMA, RNA, OTLK, and TLSA

How does Briacell Therap compare to Korro Bio?

Do analysts rate KRRO or BCTX?

Does the media favor KRRO or BCTX?

Which has better valuation and earnings, KRRO or BCTX?

Is KRRO or BCTX more profitable?

Do institutionals & insiders have more ownership in KRRO or BCTX?

Which has more volatility & risk, KRRO or BCTX?

Summary

How does Briacell Therap compare to Humacyte?

Does the media refer more to BCTX or HUMA?

Is BCTX or HUMA more profitable?

Do insiders & institutionals have more ownership in BCTX or HUMA?

Which has preferable valuation & earnings, BCTX or HUMA?

Which has more risk and volatility, BCTX or HUMA?

Do analysts recommend BCTX or HUMA?

Summary

How does Briacell Therap compare to Avidity Biosciences?

Is RNA or BCTX more profitable?

Do institutionals & insiders have more ownership in RNA or BCTX?

Does the media favor RNA or BCTX?

Do analysts recommend RNA or BCTX?

Which has higher valuation and earnings, RNA or BCTX?

Summary

How does Briacell Therap compare to Oncobiologics?

Do analysts rate OTLK or BCTX?

Does the media favor OTLK or BCTX?

Is OTLK or BCTX more profitable?

Do institutionals and insiders believe in OTLK or BCTX?

Which has stronger earnings and valuation, OTLK or BCTX?

Which has more volatility & risk, OTLK or BCTX?

Summary

How does Briacell Therap compare to Tiziana Life Sciences?

Does the media favor BCTX or TLSA?

Is BCTX or TLSA more profitable?

Do analysts rate BCTX or TLSA?

Which has preferable earnings & valuation, BCTX or TLSA?

Do insiders & institutionals have more ownership in BCTX or TLSA?

Which has more risk & volatility, BCTX or TLSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools